JP2011500806A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500806A5 JP2011500806A5 JP2010531018A JP2010531018A JP2011500806A5 JP 2011500806 A5 JP2011500806 A5 JP 2011500806A5 JP 2010531018 A JP2010531018 A JP 2010531018A JP 2010531018 A JP2010531018 A JP 2010531018A JP 2011500806 A5 JP2011500806 A5 JP 2011500806A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pyrrolo
- pyrazol
- pyrazin
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 229910052760 oxygen Inorganic materials 0.000 claims 32
- 229910052717 sulfur Inorganic materials 0.000 claims 31
- 125000005842 heteroatom Chemical group 0.000 claims 20
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 229920006395 saturated elastomer Polymers 0.000 claims 16
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 8
- 125000002393 azetidinyl group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 6
- -1 1H-pyrazol-4-yl Chemical group 0.000 claims 6
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 2
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 claims 2
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 claims 2
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 claims 2
- 230000001668 ameliorated effect Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- AMYZYDRRAXHIPU-SNVBAGLBSA-N (2r)-1-[6-[5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyrazin-2-yl]oxypropan-2-amine Chemical class C[C@@H](N)COC1=CN=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=N1 AMYZYDRRAXHIPU-SNVBAGLBSA-N 0.000 claims 1
- HAQTZVJKKNBQNQ-SNVBAGLBSA-N (2r)-2-[6-[5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyrazin-2-yl]oxypropan-1-amine Chemical class NC[C@@H](C)OC1=CN=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=N1 HAQTZVJKKNBQNQ-SNVBAGLBSA-N 0.000 claims 1
- AMYZYDRRAXHIPU-JTQLQIEISA-N (2s)-1-[6-[5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyrazin-2-yl]oxypropan-2-amine Chemical class C[C@H](N)COC1=CN=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=N1 AMYZYDRRAXHIPU-JTQLQIEISA-N 0.000 claims 1
- HAQTZVJKKNBQNQ-JTQLQIEISA-N (2s)-2-[6-[5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyrazin-2-yl]oxypropan-1-amine Chemical class NC[C@H](C)OC1=CN=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=N1 HAQTZVJKKNBQNQ-JTQLQIEISA-N 0.000 claims 1
- NHACWTVBXCUZGE-UHFFFAOYSA-N 1-[6-[5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyrazin-2-yl]azetidin-3-ol Chemical compound C1C(O)CN1C1=CN=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=N1 NHACWTVBXCUZGE-UHFFFAOYSA-N 0.000 claims 1
- RYUQEHUMEFJBIN-UHFFFAOYSA-N 1-[6-[5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyrazin-2-yl]piperidin-4-ol Chemical compound C1CC(O)CCN1C1=CN=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=N1 RYUQEHUMEFJBIN-UHFFFAOYSA-N 0.000 claims 1
- KWGCBFCBCQFNFN-UHFFFAOYSA-N 2-[4-[3-(6-piperidin-4-yloxypyrazin-2-yl)-1h-pyrrolo[2,3-b]pyridin-5-yl]pyrazol-1-yl]ethanol Chemical compound C1=NN(CCO)C=C1C1=CN=C(NC=C2C=3N=C(OC4CCNCC4)C=NC=3)C2=C1 KWGCBFCBCQFNFN-UHFFFAOYSA-N 0.000 claims 1
- KCNZNTAZCKXQAW-UHFFFAOYSA-N 2-[[6-[5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyrazin-2-yl]amino]ethanol Chemical compound OCCNC1=CN=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=N1 KCNZNTAZCKXQAW-UHFFFAOYSA-N 0.000 claims 1
- FLHIOOJOWXRXKR-UHFFFAOYSA-N 3,3,3-trifluoro-2-[6-[5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyrazin-2-yl]oxypropan-1-amine Chemical compound NCC(C(F)(F)F)OC1=CN=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=N1 FLHIOOJOWXRXKR-UHFFFAOYSA-N 0.000 claims 1
- RMERCXKBQWJSNU-UHFFFAOYSA-N 3-(6-cyclohexyloxypyrazin-2-yl)-5-(1-methylpyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=NN(C)C=C1C1=CN=C(NC=C2C=3N=C(OC4CCCCC4)C=NC=3)C2=C1 RMERCXKBQWJSNU-UHFFFAOYSA-N 0.000 claims 1
- YYEIRBSEECPYGO-UHFFFAOYSA-N 3-(6-piperidin-4-yloxypyrazin-2-yl)-1-(2,2,2-trifluoroethyl)-5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]pyrrolo[2,3-b]pyridine Chemical compound C1=NN(CC(F)(F)F)C=C1C1=CN=C(N(CC(F)(F)F)C=C2C=3N=C(OC4CCNCC4)C=NC=3)C2=C1 YYEIRBSEECPYGO-UHFFFAOYSA-N 0.000 claims 1
- QXVNTBKMWPQELL-UHFFFAOYSA-N 3-(6-piperidin-4-yloxypyrazin-2-yl)-5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1CNCCC1OC1=CN=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=N1 QXVNTBKMWPQELL-UHFFFAOYSA-N 0.000 claims 1
- QLDBOOBFMMTKLI-UHFFFAOYSA-N 3-(6-piperidin-4-yloxypyrazin-2-yl)-5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=NN(CC(F)(F)F)C=C1C1=CN=C(NC=C2C=3N=C(OC4CCNCC4)C=NC=3)C2=C1 QLDBOOBFMMTKLI-UHFFFAOYSA-N 0.000 claims 1
- SDIHVAHCAIUTLE-UHFFFAOYSA-N 3-[6-(azetidin-3-yloxy)pyrazin-2-yl]-5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1NCC1OC1=CN=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=N1 SDIHVAHCAIUTLE-UHFFFAOYSA-N 0.000 claims 1
- NIGKXPUDCBICHV-CQSZACIVSA-N 3-[6-[(3r)-piperidin-3-yl]oxypyrazin-2-yl]-5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1CCNC[C@@H]1OC1=CN=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=N1 NIGKXPUDCBICHV-CQSZACIVSA-N 0.000 claims 1
- XLIUDGBZOFWPSD-NVXWUHKLSA-N 3-[6-[(3r,4r)-3-fluoropiperidin-4-yl]oxypyrazin-2-yl]-5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound F[C@@H]1CNCC[C@H]1OC1=CN=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=N1 XLIUDGBZOFWPSD-NVXWUHKLSA-N 0.000 claims 1
- NIGKXPUDCBICHV-AWEZNQCLSA-N 3-[6-[(3s)-piperidin-3-yl]oxypyrazin-2-yl]-5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1CCNC[C@H]1OC1=CN=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=N1 NIGKXPUDCBICHV-AWEZNQCLSA-N 0.000 claims 1
- OAVHEXVWAVEAKU-UHFFFAOYSA-N 3-[[6-[5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyrazin-2-yl]amino]propan-1-ol Chemical compound OCCCNC1=CN=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=N1 OAVHEXVWAVEAKU-UHFFFAOYSA-N 0.000 claims 1
- UGGNJBTVPPMKJQ-UHFFFAOYSA-N 4-[6-[5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyrazin-2-yl]oxycyclohexan-1-ol Chemical compound C1CC(O)CCC1OC1=CN=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=N1 UGGNJBTVPPMKJQ-UHFFFAOYSA-N 0.000 claims 1
- AVLRGAAKHKPNLQ-UHFFFAOYSA-N 5-(1-ethylpyrazol-4-yl)-3-(6-piperidin-4-yloxypyrazin-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=NN(CC)C=C1C1=CN=C(NC=C2C=3N=C(OC4CCNCC4)C=NC=3)C2=C1 AVLRGAAKHKPNLQ-UHFFFAOYSA-N 0.000 claims 1
- FARXKXQFXLRXAN-UHFFFAOYSA-N 5-(1-methylpyrazol-4-yl)-3-(6-piperazin-1-ylpyrazin-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=NN(C)C=C1C1=CN=C(NC=C2C=3N=C(C=NC=3)N3CCNCC3)C2=C1 FARXKXQFXLRXAN-UHFFFAOYSA-N 0.000 claims 1
- DWOWQKVGKYFEBF-UHFFFAOYSA-N 5-(1-methylpyrazol-4-yl)-3-(6-piperidin-4-yloxypyrazin-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=NN(C)C=C1C1=CN=C(NC=C2C=3N=C(OC4CCNCC4)C=NC=3)C2=C1 DWOWQKVGKYFEBF-UHFFFAOYSA-N 0.000 claims 1
- XOXNVWUVMYCOKB-UHFFFAOYSA-N 5-(1h-pyrazol-4-yl)-3-[6-[3-(trifluoromethyl)azetidin-3-yl]oxypyrazin-2-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C=1N=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=NC=1OC1(C(F)(F)F)CNC1 XOXNVWUVMYCOKB-UHFFFAOYSA-N 0.000 claims 1
- QZVJPBOTFOEGJG-UHFFFAOYSA-N 5-[1-(cyclopropylmethyl)pyrazol-4-yl]-3-(6-piperidin-4-yloxypyrazin-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=C(C=2C=C3C(C=4N=C(OC5CCNCC5)C=NC=4)=CNC3=NC=2)C=NN1CC1CC1 QZVJPBOTFOEGJG-UHFFFAOYSA-N 0.000 claims 1
- MYMXKHWSRBHYFK-SHTZXODSSA-N C1C[C@@H](O)CC[C@@H]1NC1=CN=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=N1 Chemical compound C1C[C@@H](O)CC[C@@H]1NC1=CN=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=N1 MYMXKHWSRBHYFK-SHTZXODSSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- QOQLOXINPYFCMT-UHFFFAOYSA-N n-[2-[6-[5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyrazin-2-yl]oxyethyl]cyclohexanamine Chemical compound C1CCCCC1NCCOC(N=1)=CN=CC=1C(C1=C2)=CNC1=NC=C2C=1C=NNC=1 QOQLOXINPYFCMT-UHFFFAOYSA-N 0.000 claims 1
- LGBSCWUGPLIKEM-UHFFFAOYSA-N n-ethyl-n-piperidin-4-yl-6-[5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyrazin-2-amine Chemical compound C=1N=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=NC=1N(CC)C1CCNCC1 LGBSCWUGPLIKEM-UHFFFAOYSA-N 0.000 claims 1
- XSNSTCOTKCEWOW-UHFFFAOYSA-N n-methyl-6-[5-(1-methylpyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-3-yl]-n-piperidin-4-ylpyrazin-2-amine Chemical class C=1N=CC(C=2C3=CC(=CN=C3NC=2)C2=CN(C)N=C2)=NC=1N(C)C1CCNCC1 XSNSTCOTKCEWOW-UHFFFAOYSA-N 0.000 claims 1
- FUYYQHISLWOVHJ-UHFFFAOYSA-N n-piperidin-4-yl-n-propyl-6-[5-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyrazin-2-amine Chemical compound C=1N=CC(C=2C3=CC(=CN=C3NC=2)C2=CNN=C2)=NC=1N(CCC)C1CCNCC1 FUYYQHISLWOVHJ-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34307P | 2007-10-25 | 2007-10-25 | |
| PCT/US2008/011971 WO2009054941A1 (en) | 2007-10-25 | 2008-10-21 | Therapeutic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011500806A JP2011500806A (ja) | 2011-01-06 |
| JP2011500806A5 true JP2011500806A5 (enExample) | 2011-12-01 |
Family
ID=40579830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531018A Pending JP2011500806A (ja) | 2007-10-25 | 2008-10-21 | 治療用化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8183245B2 (enExample) |
| EP (1) | EP2211620B1 (enExample) |
| JP (1) | JP2011500806A (enExample) |
| AU (1) | AU2008317406B2 (enExample) |
| CA (1) | CA2703125C (enExample) |
| WO (1) | WO2009054941A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011500806A (ja) * | 2007-10-25 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
| JP5576370B2 (ja) | 2008-08-06 | 2014-08-20 | ファイザー・インク | Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物 |
| CN102264743B (zh) | 2008-11-25 | 2015-02-11 | 罗彻斯特大学 | Mlk抑制剂及其使用方法 |
| DE102009019962A1 (de) * | 2009-05-05 | 2010-11-11 | Merck Patent Gmbh | 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate |
| JP5719840B2 (ja) * | 2009-06-08 | 2015-05-20 | 武田薬品工業株式会社 | Ｊａｋの阻害剤としてのジヒドロピロロナフチリジノン化合物 |
| EP2338888A1 (en) * | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| UY33213A (es) * | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| EP2563125A4 (en) * | 2010-04-27 | 2013-10-02 | Merck Sharp & Dohme | AZAINDOLE AS JANUSKINASE HEMMER |
| EP2576549A4 (en) | 2010-05-24 | 2013-12-18 | Univ Rochester | Bicyclic Heteroarylkinase Inhibitors and Methods of Use |
| US8937077B2 (en) | 2010-10-22 | 2015-01-20 | Merck Sharp & Dohme Corp. | Bicyclic diamines as janus kinase inhibitors |
| DE102010049877A1 (de) | 2010-11-01 | 2012-05-03 | Merck Patent Gmbh | 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate |
| WO2012066488A2 (en) | 2010-11-17 | 2012-05-24 | Actelion Pharmaceuticals Ltd | Bridged spiro[2.4]heptane ester derivatives |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| DE102010053347A1 (de) * | 2010-12-03 | 2012-06-06 | Merck Patent Gmbh | 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren |
| DE102011008352A1 (de) * | 2011-01-12 | 2012-07-12 | Merck Patent Gmbh | 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate |
| DE102011009961A1 (de) * | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
| AU2012232658B2 (en) | 2011-03-22 | 2016-06-09 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| DE102011105469A1 (de) * | 2011-06-24 | 2012-12-27 | Merck Patent Gmbh | 7-Azaindolderivate |
| EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
| DE102011119127A1 (de) | 2011-11-22 | 2013-05-23 | Merck Patent Gmbh | 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate |
| JP6075736B2 (ja) | 2011-12-21 | 2017-02-08 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | ピロール−６員ヘテロアリール環誘導体、その合成法およびその医薬用途 |
| US20150182490A1 (en) | 2012-06-26 | 2015-07-02 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| WO2014045305A1 (en) | 2012-09-21 | 2014-03-27 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| DE102012019369A1 (de) | 2012-10-02 | 2014-04-03 | Merck Patent Gmbh | 7-Azaindolderivat |
| US10485800B2 (en) | 2012-11-30 | 2019-11-26 | The University Of Rochester | Mixed lineage kinase inhibitors for HIV/AIDS therapies |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| US9340540B2 (en) * | 2014-02-28 | 2016-05-17 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| WO2016138352A1 (en) | 2015-02-27 | 2016-09-01 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| EP4327809A3 (en) * | 2015-09-02 | 2024-04-17 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| RU2714206C1 (ru) | 2016-06-30 | 2020-02-13 | Даевунг Фармасьютикал Ко., Лтд. | Пиразолопиримидиновые производные в качестве ингибитора киназы |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| WO2018095320A1 (zh) | 2016-11-23 | 2018-05-31 | 江苏恒瑞医药股份有限公司 | 吡咯并六元杂芳环类衍生物的制备方法及中间体 |
| CN110291090A (zh) * | 2017-01-20 | 2019-09-27 | 利奥制药有限公司 | 作为新型jak激酶抑制剂的双环胺 |
| CR20200464A (es) | 2018-03-08 | 2021-04-14 | Incyte Corp | Compuestos diólicos de aminopirazina como inhibidores de pi3k-y |
| TW201940483A (zh) * | 2018-03-12 | 2019-10-16 | 美商艾伯維有限公司 | 酪胺酸激酶２介導的傳訊之抑制劑 |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| JP7636646B2 (ja) | 2019-04-09 | 2025-02-27 | オプナ バイオ ソシエテ アノニム | Ｅｐ３００またはｃｂｐの調節のための縮合アジンおよびその適応 |
| WO2020212395A1 (en) | 2019-04-16 | 2020-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| ES3075793T3 (en) | 2020-05-13 | 2026-08-07 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| AU2021273014A1 (en) | 2020-05-13 | 2022-11-17 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease |
| US20250283174A1 (en) | 2022-05-16 | 2025-09-11 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation |
| WO2026093435A1 (en) | 2024-10-31 | 2026-05-07 | Institut National de la Santé et de la Recherche Médicale | Use of jak inhibitors for enhancing the potency of immunotherapy in the treament of cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432375B2 (en) * | 2003-03-06 | 2008-10-07 | Eisai R & D Management Co., Ltd. | JNK inhibitors |
| ES2364340T3 (es) * | 2004-03-30 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | Azaindoles útiles como inhibidores de jak y otras proteína quinasas. |
| US7361764B2 (en) * | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| NZ553267A (en) * | 2004-07-27 | 2010-09-30 | Sgx Pharmaceuticals Inc | Pyrrolo-pyridine kinase modulators |
| EP1828180A4 (en) | 2004-12-08 | 2010-09-15 | Glaxosmithkline Llc | 1H-pyrrolo [2,3-BETA] PYRIDINE |
| US20060264442A1 (en) | 2005-05-18 | 2006-11-23 | Allergan, Inc. | Methods for the treatment of ocular and neurodegenerative conditions in a mammal |
| MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| JP5071374B2 (ja) * | 2005-07-14 | 2012-11-14 | アステラス製薬株式会社 | ヘテロ環ヤヌスキナーゼ３阻害剤 |
| HUE028588T2 (hu) * | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| JP2011500806A (ja) * | 2007-10-25 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
-
2008
- 2008-10-21 JP JP2010531018A patent/JP2011500806A/ja active Pending
- 2008-10-21 CA CA2703125A patent/CA2703125C/en not_active Expired - Fee Related
- 2008-10-21 AU AU2008317406A patent/AU2008317406B2/en not_active Expired - Fee Related
- 2008-10-21 US US12/682,612 patent/US8183245B2/en not_active Expired - Fee Related
- 2008-10-21 EP EP08841687.0A patent/EP2211620B1/en not_active Not-in-force
- 2008-10-21 WO PCT/US2008/011971 patent/WO2009054941A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2703125A1 (en) | Pyrazinyl-substituted pyrrolo[2,3-b]pyridines, compositions thereof, and their use in the treatment of cancer | |
| US11795164B2 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| JP2019530695A5 (enExample) | ||
| US9809545B2 (en) | Factor XIa inhibitors | |
| JP2012502099A5 (enExample) | ||
| IL263511A (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| ES2967119T3 (es) | Compuestos inhibidores de metaloenzimas | |
| HRP20160421T1 (hr) | Derivat azola | |
| RU2012136643A (ru) | [5,6]- гетероциклическое соединение | |
| CA3071760A1 (en) | Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors | |
| JP2013528204A5 (enExample) | ||
| JP2019513135A (ja) | Ｄｕｂ阻害剤としての１−シアノピロリジン誘導体 | |
| JP2011503166A5 (enExample) | ||
| JP2014516074A5 (enExample) | ||
| JP2019537571A5 (enExample) | ||
| AR102852A1 (es) | Inhibidores heterocíclicos de la calicreína plasmática | |
| US20190142812A1 (en) | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | |
| CA2642922A1 (en) | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | |
| CA2670760A1 (en) | Naphthyridine compounds as inhibitors of akt activity | |
| US11660301B2 (en) | Combination of ATR kinase inhibitors with PARP inhibitors | |
| RU2011134868A (ru) | N-замещенные насыщенные гетероциклические сульфоновые соединения с активностью агонистов рецептора св2 | |
| JP2018520170A5 (enExample) | ||
| JP2020502230A5 (enExample) | ||
| JP2021535134A5 (enExample) | ||
| TW201302730A (zh) | 吡唑化合物 |